

Olympic Ophthalmics Announces Issuance of Two Seminal Patents for its Neuromodulation Technology

Patents cover iTEAR's unique neurostimulation pathways, device, and comfort features

ISSAQUAH , WA, USA, April 22, 2021 /EINPresswire.com/ -- Olympic Ophthalmics, a leading [neurostimulation](#) medical device company, today announced that the U.S. Patent and Trademark Office has issued two seminal neuromodulation patents. These patents cover the unique neural target to activate the parasympathetic pathway through the trigeminal nerve. Modulation of this neural pathway has been shown to have therapeutic benefit for [dry eye](#), sinusitis, migraines, and neuropathic pain. The patents also cover the device and its mechanical features designed for patient comfort, ease of use, and connection to the Doctor. The company has another two dozen patents pending in the U.S. and abroad.

"Receiving these issued patents which cover current and future product development is an important milestone for the company, said Michael Gertner, CEO of Olympic Ophthalmics. "These patents solidify our leadership in the rapidly evolving field of neuromodulation to increase tear production and improve tear film homeostasis in adult patients, including those with dry eye disease. With the use of masks and increased screen time, there are millions of patients who can benefit from this technology."

The following patents have been issued:

US 10,952,923 directed to claims around stimulating the external nasal nerve to treat dry eye and meibomian gland disease

US 10,842,710 directed to claims around stimulating tear production and meibomian gland secretion using the specific parameters in the iTEAR100 device including frequency, force, and displacement.

About iTEAR®100

iTEAR®100 was cleared by FDA in 2020 and is indicated to temporarily increase natural tear production in adult patients, requiring a prescription from an eye care provider. The iTEAR device has been proven to increase natural tear production in a large study which was published in 2020 in the Journal of Translational Vision Science and Technology. Importantly, iTEAR100 is drug free and non-invasive. There are no chemicals placed inside the body or in the eye. As with

other neurostimulation technologies, it uses the body's own stimulation pathways to produce a therapeutic outcome. For more information contact info@oo-med.com.

About Olympic Ophthalmics

Founded in 2017, Olympic Ophthalmics is part of the \$10B neuromodulation market dedicated to harnessing the power of the body's own nerve pathways to treat acute and chronic diseases with simple and easy to use home devices.

Michael Gertner
Olympic Ophthalmics
info@oo-med.com

This press release can be viewed online at: <https://www.einpresswire.com/article/538734850>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.